|
February 2002
NIAID's HIV Prevention Trials Network (HPTN)
In an effort to reduce the worldwide spread of HIV, the National Institutes
of Health (NIH) created the HIV Prevention Trials Network (HPTN), a global
network of clinical trial sites that explores non-vaccine prevention strategies
to reduce HIV transmission. The new network will test and develop both
biomedical and behavioral intervention programs. Because HIV is transmitted
via different routes in different populations, developing a variety of
HIV prevention strategies will have a significant impact on reducing transmission
rates and slowing the spread of HIV worldwide.
In addition to the National Institute of Allergy and Infectious Diseases
(NIAID), other NIH Institutes co-sponsoring the HPTN include the National
Institute of Child Health and Human Development; the National Institute
on Drug Abuse; and the National Institute of Mental Health.
The HPTN evolved from NIAID's HIV Network for Prevention Trials (HIVNET)
program, which conducted Phase I, II and III clinical trials at U.S.
and international sites. The HPTN will continue to expand the multidisciplinary
research agenda established by the HIVNET as well as build on the HIVNET's
many accomplishments. These accomplishments include the discovery of
nevirapine as an effective, affordable drug used to prevent mother-to-infant
HIV transmission in developing countries, and the establishment of the
initial safety and acceptability of two new non-detergent microbicides.
Research through the HPTN is carried out through HIV Prevention Trials
Units (HPTUs) located at 15 sites in the United States and 14 sites
overseas in Africa, Asia, Europe and South America. The HPTN scientific
agenda is divided into six main areas of research, each carried out
by specialized Science Working Groups (SWGs):
- Microbicide SWG develops and tests topical
antimicrobial agents, such as creams, gels and foams, that could be
applied vaginally or rectally to prevent the sexual transmission of
HIV.
- Perinatal SWG evaluates a variety of strategies,
such as antiviral drugs, antibiotics and therapeutic vaccines, that
would lower viral load to reduce the risk of mother-to-child HIV transmission.
- Antiretroviral Therapy SWG - evaluates the impact of antiretroviral
therapies in reducing the infectiousness of HIV-infected individuals.
- STD Control SWG evaluates programs to control
or reduce STD infections as a means of decreasing the risk of acquiring
and transmitting HIV infection.
- Behavioral SWG develops and tests new behavioral
interventions, such as community education and counseling, to help
people reduce their risk of exposure to HIV.
- Substance Use SWG studies the effect of
interventions to reduce injection and noninjection drug use,
and alcohol and other substance use, as a means of slowing the spread
of HIV through shared needles and sexual intercourse.
In developing its scientific agenda, the HPTN includes community members
who participate in the discussion of important issues, such as study
design, recruitment plans, incentives for trial volunteers, informed
consent, risk-reduction interventions and dissemination of research
findings. HPTN investigators involve their local communities to promote
the exchange of information and ideas, and to ensure that social, cultural
and political values are respected in each community where research
is conducted.
The HPTN comprises a Coordinating and Operations Center
at Family Health International in Durham, NC (Dr. Ward Cates, principal
investigator), which manages the scientific aspects of the network from
study design and development to analyses; a Statistical and
Data Management Center at the Fred Hutchinson Cancer Research
Center and the University of Washington in Seattle, WA (Dr. Thomas Fleming,
principal investigator), which manages the HPTN databases and guides
protocol teams on the statistical components of study design and analyses
of study data; and a Central Laboratory at Johns Hopkins
University in Baltimore, MD (Dr. Brooks Jackson, principal investigator),
which collects, tests and reports results from biologic samples and
identifies new technologies to advance the scientific agenda of the
network.
The domestic and international clinical sites and their principal investigators
are listed below.
UNITED STATES
Alabama
- University of Alabama at Birmingham - Sten Vermund, M.D., Ph.D.
California
- Los Angeles County Department of Health - Peter Kerndt, M.D., M.P.H.
- University of California Los Angeles - Yvonne J. Bryson, M.D.
- University of California San Francisco - Tsungai Chipato, MBChB
Maryland
- Johns Hopkins University, Baltimore - Robert C. Bollinger, M.D.,
M.P.H.
- Johns Hopkins University, Baltimore - David Celentano, Sc.D., M.P.H.
- Johns Hopkins University, Baltimore - Laura Guay, M.D.
- Johns Hopkins University, Baltimore - J. Brooks Jackson, M.D., M.B.A.
- Johns Hopkins University, Baltimore - Taha E. Taha, M.D., Ph.D.
Massachusetts
- Fenway Community Health, Boston - Kenneth H. Mayer, M.D.
- Harvard University School of Public Health, Boston - Wafaie Fawzi,
M.D., Dr.P.H.
New York
- Columbia University Health Sciences, New York - Wafaa El-Sadr, M.D.,
M.P.H.
North Carolina
- University of North Carolina, Chapel Hill - Robert Ryder, M.D.
Pennsylvania
- University of Pennsylvania, Philadelphia - David Metzger, Ph.D.
Washington
- Harborview Medical Center, Seattle - Connie Celum, M.D., M.P.H.
INTERNATIONAL
Africa
Malawi
- Malawi College of Medicine, Blantyre - George Liomba, M.D.
South Africa
- South African Medical Research Council, Durban - Gita Ramjee, M.D.
Tanzania
- Muhimbili University, College of Health Sciences, Dar Es Salaam
- Gernard Msamanga, M.D., D.Sc.
Uganda
- Makerere University School of Medicine, Kampala - Francis Mmiro,
MBChB
- Makerere University School of Medicine, Kampala - Nelson Sewankambo,
M.D.
Zambia
- Lusaka District Health Board and University Teaching Hospital, Lusaka
- Moses Sinkala, M.D./Chewe Lou, M.D., M.Sc.
Zimbabwe
- University of Zimbabwe, Harare - Tsungai Chipato, MBChB
Asia
China
- National Center for AIDS Prevention and Control, Beijing - Yiming
Shao, M.D., Ph.D.
India
- IHI/YRG Care, Chennai - Suniti Solomon, M.D.
- National AIDS Research Institute (NARI), Pune - Sanjay M. Mehendale,
M.D., MBBS, M.P.H.
Thailand
- Chiang Mai University, Chiang Mai - Chirasak Khamboonruang, M.D.,
Ph.D.
Europe
Russia
- St. Petersburg State University - Andrei Kozlov, Ph.D.
South America
Brazil
- Oswaldo Cruz Foundation, Rio de Janiero - Francisco Inacio Bastos,
M.D. Peru
- Universidad Peruana Cayetano Heredia, Lima - Jorge Sanchez, M.D.,
M.P.H.
NIAID is a component of the National Institutes of Health
(NIH), which is an agency of the Department of Health and Human Services.
NIAID supports basic and applied research to prevent, diagnose, and
treat infectious and immune-mediated illnesses, including HIV/AIDS
and other sexually transmitted diseases, illness from potential agents
of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma
and allergies.
News releases, fact sheets and other NIAID-related
materials are available on the NIAID Web site at http://www.niaid.nih.gov.
Prepared by:
Office of Communications and Public Liaison
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, MD 20892
Publications Home | Search
Last Updated November 21, 2003 (alt)
|